RT Book, Section
A1 Lue, Tom f.
A2 McAninch, Jack W.
A2 Lue, Tom F.
SR Print(0)
ID 56950308
T1 Chapter 39. Male Sexual Dysfunction
T2 Smith & Tanagho's General Urology, 18e
YR 2013
FD 2013
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-162497-8
LK accessmedicine.mhmedical.com/content.aspx?aid=56950308
RD 2024/04/18
AB It  is  estimated  that  more  than  half  of  men  aged  40–70  years  in  the  United  States  are  unable  to  attain  or  maintain  a  penile  erection  sufficient  for  satisfactory  sexual  performance.  Advances  in  pharmacologic  therapy  for  erectile  dysfunction  (ED),  coupled  with  a  better  understanding  of  male  sexual  dysfunction,  have  resulted  in  greater  numbers  of  patients  seeking  care  for  sexual  concerns.  Oral  phosphodiesterase  type-5  inhibitors  (PDE-5Is)  have  emerged  as  the  preferred  first-line  treatment  of  ED  worldwide  due  to  their  efficacy,  ease  of  use,  and  patient  safety.  Erectile  function  can  now  be  evaluated  by  the  response  to  these  agents  at  home  or  intracavernous  injection  (ICI)  of  vasoactive  agents  in  the  office,  and  improved  diagnostic  tests  can  differentiate  among  types  of  impotence.  Patient  satisfaction  with  penile  prostheses  is  high,  as  the  latest  generation  of  devices  is  more  sophisticated  and  durable  than  ever.  Current  treatments  continue  to  evolve  and  new  therapies  such  as  stem  cells  and  gene  therapies  may  represent  the  next  generation  of  more  physiologic  and  disease-specific  solutions  to  various  types  of  ED  (Bahk  et  al,  2010;  Lin  et  al,  2009;  Melman  et  al,  2007).